Bavarian Biotech Report 2011/2012 (7MB) - Bio M

More documents

Recommendations

Info

Last but not least, the IZB start-up centres were especiallydesigned to satisfy the requirements of the biotechindustry with its branches in the north of Munich (Freising-Weihenstephan)and especially Martinsried-Planeggat the southern city limits of Munich. Together they offerfacilities with more than 25,000 m 2 of laboratory andoffice space that currently house more than 50 tenantsand almost 700 employees. Although it was designed fora modest 800 m 2 when the first foundation stone waslaid in 1995, the location between the GrosshadernCampus Hospital of the LMU and the Max Planck Institutesfor Biochemistry and Neurobiology – and mostrecently also the Faculty of Biology, as well as Chemistryand Pharmacy, and the Gene Centre of the LMU – hasturned out to be perfect. The building expansions werejust capable of keeping pace with the companies'expansion requests or – as was the case of the ProterosBiostructures company – were satisfied by a privatelyconstructed laboratory building in close proximity in2011. In turn, this enabled the recruitment of additionalcompanies.When a start-up centre exceeds a certain size and complexitywith all of its local and regional networks inpolitics and administration, it is advisable to establish anadditional management organisation that focuses ontechnology and product development. This parallelismexisted in Martinsried and the Greater Munich area fromthe very beginning: Bio M was already established in 1997as an institution with its own funding; its purpose wasand still is to help entrepreneurs – in good times and inbad – with advice and support in an industry that wasstill in its infancy. More than 150 company start-ups havebeen assisted since then. This is a quite respectable trackrecord in view of the approximately 130 companiesexisting today.best fruit or have already secured a portion of it. Butwhat does the future look like as more “real” productsare generated in the pharmaceutical sector, whichhopefully means an increasing number of approvedbiotech products from the Bavarian pipeline?The German healthcare system as such will ultimatelypose a great challenge. There is much uncertainty as towhether a system dating from the time of Bismarck cancope with the societal challenges of the present and thefuture. The Bavarian companies would certainly love toannounce positive news about FDA or EMA approvals inthe near future. However, an oath and a decision as towhether a medicine is successful or not is primarilydependent upon its reimbursability – and this might noteven be attained for quite a while after the approval.Bavarian companies have already shown many timesover that they are capable of bringing innovative drugsto market based on their scientific foundation and technologicalexpertise. TRION Pharma from Munich demonstratedthis with Removab in 2009, the first tri-functionalantibody that was invented, developed and brought toapproval on location in Germany by a biotech company.However, they also discovered that reimbursability is amajor issue once this process has been completed.As patients realise the necessity and benefit of a newtherapy and the health system also learns that a welltreatedniche disease saves real money, the biotechSMEs with less financial means can demonstrate thegreater benefit over standard medication in smallerclinical studies with better characterised (stratified)patient groups. They must even be able to do this inorder to present a proof of legitimacy for their originalidea – and to show this innovation is paying off.The (scientific and infrastructural) ground has beenexcellently prepared for decades in Bavaria; the seed hasborne fruit that has already been harvested in somecases. In other cases, companies are trying to reach theLet us now look at the facts and figures of the 2011 yearin Bavarian biotechnology.14
Facts and FiguresNumber of CompaniesAccording to our survey, the number of biotech SMEs inBavaria in 2011 amounts to 166 (- 3 compared to 2010).126 of these are domiciled in the Greater Munich Area.The Regensburg/Eastern Bavaria region still has thesecond-largest company cluster in Bavaria, with morethan 26 dedicated biotech companies (SMEs and non-SMEs) and in addition some 20 companies working inthe fields of medical technology, biomaterials and industrialbiotechnology.Additionally 35 national or international subsidiaries (inthis Report referred to as “non-SMEs”) are working inBiotechnology – of which the Roche Diagnostics inPenzberg, 60 kilometers south of Munich, with more than4800 employees is the largest and most complete inrespect to the value added chain. Penzberg is also thelargest research, development and production locationwithin the whole Roche Corporation. The Roche groupinvested nearly € 2 billion in the development of thePenzberg site since the late 1990s. As a Centre of Excellencefor the technical research and development oftherapeutic proteins, researchers here focus on thediscovery of new protein-based drugs in oncology.In Pharma, more global players are located in Bavaria:Novartis Germany in Nuremberg with almost 2000employees, BristolMyersSquibb, GlaxoSmithKline,BIOTECH/PHARMA COMPANIES IN BAVARIA2006 (total: 304) 2007 (total: 310) 2008 (total: 323)2009 (total: 324) 2010 (total: 329) 2011 (total: 321)Biotech companies(SMEs)Biotech companies(non-SMEs)CROsPharma companiesSuppliers/CMOs262830333335373536363634303031303128565961606058number of companies 20 40 60 80 100 120 140 160155158165165169166REGIONAL ALLOCATIONBavaria total (total: 321) Greater Munich Area (total: 256)Biotech companies(SMEs)166126Biotech companies(non-SMEs)3529CROs5850Pharma companies3427Suppliers/CMOs2824number of companies 20 40 60 80 100 120 140 16015
Page 2 and 3: Our research benefits your health.T
Page 4 and 5: ImprintEditorial staff: Georg Kää
Page 6 and 7: Select IMGM as your outsourcing par
Page 8 and 9: The 2011 Biotech Year in Bavaria -A
Page 10 and 11: Due to this focus that was establis
Page 12 and 13: Furthermore, the continued interest
Page 16 and 17: Company FoundationsMerck-Sharp & Do
Page 18 and 19: Total number of employees in the Ba
Page 20 and 21: PHASE II4SC: Hepatocellular carcino
Page 22 and 23: Deals, Cooperation, Mergers, Financ
Page 24 and 25: M&A-ActivityIn early 2011 the acqui
Page 26: Due to the increasing number of new
Page 29: one so called “innovation allianc
Page 32 and 33: 4SC AGBIOTECH THERAPEUTICS & DIAGNO
Page 34 and 35: Contact:Dr. Luc St-OngeFraunhoferst
Page 36 and 37: Contact:Dr. Lars WassillWerkstr. 2D
Page 38 and 39: Apceth GmbH & Co. KGBIOTECH THERAPE
Page 40 and 41: Contact:Dr. Gundel HagerBahnhofstr.
Page 42 and 43: Bernina Plus GmbHBIOTECH THERAPEUTI
Page 44 and 45: Biontex Laboratories GmbHBIOTECH DE
Page 46 and 47: Carl Zeiss MicroImaging GmbHBIOTECH
Page 48 and 49: ChemDiv, Inc.CROContact:Dr. Anna Ni
Page 50 and 51: conoGenetix biosciences GmbHBIOTECH
Page 52 and 53: CoreLab Partners Europe GmbHCROCont
Page 54 and 55: Davids Biotechnologie GmbHBIOTECH D
Page 56 and 57: Dynamic BiosensorsBIOTECH DNA/PROTE
Page 58 and 59: Contact:Uschi LangGoethestr. 4D-803
Page 60 and 61: Eurofins MWG OperonBIOTECH DNA/PROT
Page 62 and 63: FGK Clinical Research GmbHCROContac
Page 64 and 65:
GeneArt AGBIOTECHContact:Prof. Dr.
Page 66 and 67:
Contact:Dr. Korbinian GroteBayerstr
Page 68 and 69:
Contact:Peter Paul SchikoraMühlfel
Page 70 and 71:
Contact:Kurt MartinJosef-Engert-Str
Page 72 and 73:
ibidi GmbHBIOTECH DEVICES & REAGENT
Page 74 and 75:
Immumed GmbH -Gesellschaft für ang
Page 76 and 77:
INHECO GmbHBIOTECH DEVICES & REAGEN
Page 78 and 79:
IRIS Biotech GmbHPHARMA & CHEMICAL
Page 80 and 81:
KLIFOVET AGCROContact:Dr. Klaus Hel
Page 82 and 83:
LEUKOCARE AGBIOTECH DEVICES & REAGE
Page 84 and 85:
medicomp GmbHCROContact:Dr. med. ve
Page 86 and 87:
Contact:Dr. Erwin SoutschekFlorians
Page 88 and 89:
MLL Münchner Leukämie Labor GmbHB
Page 90 and 91:
multimmune GmbHBIOTECH THERAPEUTICS
Page 92 and 93:
NanoScape AGPHARMA & CHEMICAL INDUS
Page 94 and 95:
nexttec GmbHBIOTECH DNA/PROTEIN ANA
Page 96 and 97:
Contact:Michael AlmstetterAm Klopfe
Page 98 and 99:
PAN Biotech GmbHBIOTECH DEVICES & R
Page 100 and 101:
Pharma Stulln GmbHPHARMA & CHEMICAL
Page 102 and 103:
Phytochem Referenzsubstanzen GbRmbH
Page 104 and 105:
PreSens Precision Sensing GmbHBIOTE
Page 106 and 107:
Contact:Dr. Torsten NeuefeindBunsen
Page 108 and 109:
Ridom GmbHBIOTECH BIOINFORMATICSCon
Page 110 and 111:
SERVIER Deutschland GmbHPHARMA & CH
Page 112 and 113:
SSS International Clinical Research
Page 114 and 115:
TILL Photonics GmbHBIOTECH DEVICES
Page 116 and 117:
Tripos InternationalBIOTECH BIOINFO
Page 118 and 119:
vertis Biotechnologie AGBIOTECH DNA
Page 120 and 121:
Wilex AGBIOTECH THERAPEUTICS & DIAG
Page 124:
Where the future becomes realityHOT
show all

Bavarian Biotech Report 2011/2012 (7MB) - Bio M

Create successful ePaper yourself

Delete template?

Save as template?